Competitive Intelligence
A standing signal, not a one-time audit.
Weekly AI-harvested intelligence across paid media, organic search, AI answers, patient forums, and trade press. You give us a watchlist; we deliver continuous signal, archived to canon so the creative engine learns from it too.
Competitors tracked
12
Competitor A, Pfizer, Novartis, generics
+ 3 pipeline-adjacent biotechs
Signals · last 7 days
23
5 high-priority
Auto-classified by relevance
Forum mentions · Compound DT-204
Sample
187
illustrative trend
Reddit, patient groups, X/Twitter
Sentiment · last 30d
Sample
+0.62
once data flows
Range −1 to +1 · weighted by reach
Live feed
This week's intelligence
5 high8 med10 low
Competitor A · paid Meta● high · 2h ago
New disease-state campaign live targeting cardiology HCPs.
Creative emphasizes 'beyond steroids' positioning. 4 unique ad sets observed. Targeting US-only, 35–65, cardiology profession + 'rare cardiology indication' interest layer.
Direct competitorPaidHCP
Artifacts: 3 reels archived · 1 carousel · 6 frames archived
Generic rilonacept · search● high · 6h ago
Estimated launch volume tracking 14% above forecast.
New SEO push detected on 'rilonacept generic' (1,900 vol/mo). Amneal landing page now ranks #2 organic for the term. Compound DT-204 currently #9.
GenericSEOCost
Artifacts: Landing page snapshot · SERP archive · 04-26
ChatGPT · GEO scan● high · 9h ago
Compound DT-204 mentioned in 3 of 5 prompts on 'rare cardiology indication treatment.'
Competitor A mentioned 4 of 5. We're losing the AI surface. Specific erosion: 'best treatment for pericarditis flares'. Competitor A primary, Compound DT-204 tertiary. Recommend GEO-targeted content drop.
GEODirect competitorAI answers
Artifacts: Full prompt log · 50 prompts · Comparison table
Reddit · r/pericarditismed · 1d ago
23 mentions of 'cost' as primary barrier this week, up from 8 last week.
Caregiver subreddit driving the spike. Three distinct threads. Sentiment: frustrated but not anti-brand. Opportunity: caregiver-facing cost & access content.
Patient communityCostCaregiver
Artifacts: Thread links · 3 · Mention timeline
Pfizer pipeline · DT-387 adjacencymed · 1d ago
Phase 2 readout for IL-1 antagonist in pericarditis adjacent indication.
Worth flagging to medical. Not a direct rilonacept competitor today, but watching mechanism overlap given DT-387 trajectory.
PipelineMechanism overlap
Artifacts: Press release · Trial registry update
Watchlist
Who we're tracking
Competitor A (Kineret · anakinra)high
Direct competitor · 2h ago
New Meta campaign · 'beyond steroids' positioning
Generic rilonacept (Amneal · launch)high
Generic threat · 6h ago
Launch volume tracking 14% above forecast. New SEO push 'rilonacept generic'.
Pfizer (DT-387 adjacency)med
Pipeline adjacency · 1d ago
Phase 2 readout for IL-1 antagonist in adjacent indication.
Novartis (Ilaris)med
Adjacent IL-1 · 2d ago
EMA submission for new indication. US implications unclear.
Reddit · r/pericarditismed
Patient community · 1d ago
Cost discussion thread up 23 mentions/wk. Caregiver subreddit driving spike.
ChatGPT GEO surfacehigh
AI answers · 9h ago
Compound DT-204 mentioned in 3 of 5 prompts on RP treatment. Competitor A mentioned 4 of 5.
Cardiology Today (KOL site)low
Trade press · 3d ago
Editorial referenced steroid-overuse in RP. Compound DT-204 not cited.
Add or edit watchlist entries from theSettings panel.
Closed loop · intelligence to corpus
The signal feeds back into the brand brain.
Intelligence is not a one-way feed. Every standing stream is scored against the essence anchor at ingest, and pieces that clear the relevance threshold land in the proposal inbox as candidate brand corpus additions. From there: human approval, never automatic ingest. A reviewer accepts, rejects, or annotates each proposed piece before it joins the corpus and starts informing retrieval at generation time. Live monitoring, relevance scoring against essence, proposed corpus ingest, human approval before any addition. The intel layer keeps the per-brand text adapter calibrated to where the market actually is.
Share of voice
Compound DT-204 vs the field, last 30 days
Compound DT-20442%
Competitor A (Kineret)36%
Generic rilonacept14%
Other / general medical8%
Share of digital mentions across paid, organic, social, AI answers, patient forums. Competitor A closing the gap on AI-answer surface specifically, addressed in Discovery → GEO.
Forward thisOne click to the right page for whoever you need to loop in.
What's underneathArchitecture · advisors · published thinking.
Talk to us30 minutes with Maha + Zein. No deck, no sales motion. We answer your questions.